Cranial nerve neuropathy

Summary

Cranial nerve neuropathy (MONDO:0003569) is a disease (an umbrella term covering 17 Mondo subtypes) and 5 clinical trials. Top therapeutic interventions include ferumoxytol and gadolinium. A subtype of nervous system disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Umbrella term: 17 Mondo subtypes
• Clinical trials: 5

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	cranial nerve neuropathy
Mondo ID	MONDO:0003569
MeSH	D003389
DOID	DOID:5656
NCIT	C26733
SNOMED CT	73013002
UMLS	C0010266
MedGen	1160
Anatomy (UBERON)	UBERON:0034713
Is cancer (heuristic)	no

Also known as: cranial nerve disease · cranial nerve disorder · cranial neuron projection bundle disease · cranial neuron projection bundle disease or disorder · cranial neuropathy · disease of cranial neuron projection bundle · disease or disorder of cranial neuron projection bundle · disorder of cranial nerve · disorder of cranial neuron projection bundle

Disease family

This is a subtype of nervous system disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › nervous system disorder › cranial nerve neuropathy

Related subtypes (71): congenital nervous system disorder, central nervous system disorder, autoimmune disorder of the nervous system, peripheral nervous system disorder, neuronitis, diplegia of upper limb, retinal disorder, developmental disability, restless legs syndrome, movement disorder, toxic encephalopathy, Barre-Lieou syndrome, Gerstmann syndrome, drug-induced akathisia, drug-induced dyskinesia, stiff-person syndrome, Worster-Drought syndrome, corneal-cerebellar syndrome, pachygyria-intellectual disability-epilepsy syndrome, porencephaly-cerebellar hypoplasia-internal malformations syndrome, symmetrical thalamic calcifications, neonatal brainstem dysfunction, primary orthostatic hypotension, rippling muscle disease with myasthenia gravis, periodic paralysis, qualitative or quantitative protein defects in neuromuscular diseases, specific learning disability, cerebellar hypoplasia-tapetoretinal degeneration syndrome, locked-in syndrome, dopa-responsive dystonia, idiopathic recurrent stupor, chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids, spontaneous periodic hypothermia, Sydenham chorea, duplication of the pituitary gland, Balint syndrome, paraneoplastic neurologic syndrome, persistent idiopathic facial pain, serotonin syndrome, hypothalamic adipsic hypernatraemia syndrome, exercise-induced malignant hyperthermia, perineural cyst, neuromuscular disease, neuromyelitis optica, AL amyloidosis, AA amyloidosis, neuroleptic malignant syndrome, infectious disorder of the nervous system, central nervous system malformation, synaptopathy, nervous system neoplasm, sensory ganglionopathy, radiculitis, wet beriberi, perceptual disorders, prepubertal anorexia nervosa, neurocutaneous syndrome, neurovascular disorder, Wallerian degeneration, nervous system injury, neurosarcoidosis, neuroendocrine disorder, tubulinopathy, atactic disorder, hereditary neurological disease, meningitis-retention syndrome, KIF1A related neurological disorder, neurological pain disorder, neurodevelopmental disorder, post 5-alpha-reductase inhibitors treatment syndrome, post-selective serotonin reuptake inhibitor sexual dysfunction

Subtypes (17): vestibulocochlear nerve disorder, ocular motility disease, hypoglossal nerve disorder, facial nerve disorder, optic nerve disorder, cranial nerve neoplasm, accessory nerve disorder, glossopharyngeal nerve disorder, olfactory nerve disorder, cranial nerve palsy, trigeminal nerve disorder, third cranial nerve disorder, pseudobulbar palsy, trochlear nerve disorder, jaw-winking syndrome, cranial neuralgia, abducens nerve disorder

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 5.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	3
PHASE2	1
PHASE1/PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03270059	PHASE2	RECRUITING	Gadolinium and Ferumoxytol MRI in Diagnosing Patients With Abnormalities in the Central Nervous System
NCT04151082	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	High Dose Steroid Therapy (Prednisone or Methylprednisolone) for the Improvement of Symptoms of Late Radiation-Associated Lower Cranial Neuropathy in Oropharyngeal Cancer Survivors
NCT07135063	Not specified	NOT_YET_RECRUITING	Cranial Nerve Functions in Behçet’s Disease and Their Relationship With Clinical Parameters
NCT01932255	Not specified	WITHDRAWN	CSF Leak Following Microvascular Decompression: the Benefit of Routine Postoperative Lumbar Tap
NCT03659760	Not specified	COMPLETED	: Association of Melatonin Levels and Light and Noise Isolation in ICU

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
FERUMOXYTOL	4	1
GADOLINIUM	2	1
CHEMBL15720	0	1